Patient-reported Outcomes in the Treatment of Schizophrenia

Phase 3CompletedNCT00230828

Solvay Pharmaceuticals

Overview

Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Schizophrenia

Interventions

bifeprunoxDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participate in S1543003 and S1543004 in the U.S. sites Exclusion Criteria: * Participate in S1543003 and S1543004 other than U.S. sites

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.